CompletedPhase 3NCT02118961

Study of BK1301 (DTaP Vaccine) as a Booster in Adolescents

Studying Diphtheria

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Tanabe Pharma Corporation
Principal Investigator
Shintaro Okada, M.D., Ph.D.
Osaka University
Intervention
Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed (DTaP vaccine, BK1301)(biological)
Enrollment
446 enrolled
Eligibility
11-12 years · All sexes
Timeline
20142014

Study locations (7)

Collaborators

The Research Foundation for Microbial Diseases of Osaka University

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT02118961 on ClinicalTrials.gov

Other trials for Diphtheria

Additional recruiting or active studies for the same condition.

See all trials for Diphtheria

← Back to all trials